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ABSTRACT
Introduction: For the optimal management of children
with cystic fibrosis, there are currently no efficient
tools for the precise adjustment of pancreatic enzyme
replacement therapy, either for advice on appropriate
dietary intake or for achieving an optimal nutrition
status. Therefore, we aim to develop a mobile
application that ensures a successful nutritional
therapy in children with cystic fibrosis.
Methods and analysis: A multidisciplinary team of
12 partners coordinate their efforts in 9 work packages
that cover the entire so-called ‘from laboratory to
market’ approach by means of an original and
innovative co-design process. A cohort of 200 patients
with cystic fibrosis aged 1–17 years are enrolled. We
will develop an innovative, clinically tested mobile
health application for patients and health professionals
involved in cystic fibrosis management. The mobile
application integrates the research knowledge and
innovative tools for maximising self-management with
the aim of leading to a better nutritional status, quality
of life and disease prognosis. Bringing together
different and complementary areas of knowledge is
fundamental for tackling complex challenges in disease
treatment, such as optimal nutrition and pancreatic
enzyme replacement therapy in cystic fibrosis. Patients
are expected to benefit the most from the outcomes of
this innovative project.
Ethics and dissemination: The project is approved
by the Ethics Committee of the coordinating
organisation, Hospital Universitari La Fe (Ref: 2014/
0484). Scientific findings will be disseminated via
journals and conferences addressed to clinicians, food
scientists, information and communications technology
experts and patients. The specific dissemination working
group within the project will address the wide audience
communication through the website (http://www.
mycyfapp.eu), the social networks and the newsletter.
INTRODUCTION
Cystic ﬁbrosis (CF) is the most common life-
threating autosomal inherited disease in
Europe, with over 38 000 cases of CF currently
registered in Europe.1 Along with pulmonary
dysfunction and recurrent lung infections, the
majority of patients (85%) suffer from life-
long pancreatic insufﬁciency (PI), which
leads to maldigestion of foods and malabsorp-
tion of nutrients, especially lipids. In fact, pan-
creatic enzyme deﬁciency is occurring in
∼50% of infants by the age of 2 with a further
28% of the cases developing PI in early child-
hood.2 These malfunctions secondarily cause
malnutrition, fat-soluble vitamin deﬁciencies
and gastrointestinal symptoms.
There is high-grade evidence that maintain-
ing normal growth and nutrition adds
10 years more to the median survival since a
close relationship between pulmonary func-
tion and nutritional status has been repeat-
edly ascertained.2–4
Strengths and limitations of this study
▪ Innovative evidence-based method for pancreatic
enzyme replacement therapy adjustment and self-
management by means of a mobile application.
▪ Multidisciplinary team of experts for an integra-
tive and co-designed patients-directed approach.
▪ Envisaged medium-term to long-term market
uptake of the resulting mobile health application.
▪ Limited but statistically significant number of
patients from five European countries will be
included in the clinical validation.
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Malnutrition and growth stunting can only be avoided
by accurate pancreatic enzyme replacement therapy
(PERT) and close nutritional follow-up, as well as by early
nutritional support and intervention. Nowadays, PERT
consists of oral supplements containing a mixture of pan-
creatic enzymes—amylases, proteases and especially
lipases—that have to be taken with every meal, while
nutritional therapy relies on a high-energy and high-fat
diet.5–9 However, at present, there is a lack of evidence-
based methods to adjust PERT dosing and there are few
handy tools or resources adequately available to promote
a balanced and adapted diet (ﬁgure 1).5 10 11
Current recommendations for PERT dose adjustment
rely on low level of evidence12 and counsel a number of
units of lipase per gram of lipids. This means that in
every meal, fat content should be known by the patient to
estimate the corresponding PERT dose. The only way to
achieve this would be by roughly estimating fat content
from nutritional information databases and those should
be easily available for patients. This approach is challen-
ging for the patients and imprecise to maintain satisfac-
tory levels of fat absorption. In this regard, clinical trials
aimed at elucidating maldigestion in CF have led to
inconsistent conclusions.5 Therefore, the demand for an
evidence-based criterion for PERT adjustment has been
highlighted,5 10 13 and the corresponding development
of new innovative tools is imperative.
Dietary lipids need to be accessible to digestive
enzymes so that digestion and absorption can occur.
The food matrix is dissociated through the digestion
process, thus allowing the release of the embedded
lipids and the access of the enzymes (lipases) to their
substrates (lipids).5 14 Recent advances in food science
research revealed that the different food structures
modulate fatty acids release during digestion and their
ﬁnal metabolic fate.15–17 In addition, pancreatic lipase
exhibits different hydrolytic activity depending on the
intramolecular structure of the lipids.14 18 19 Therefore,
lipolysis may cause different kinetics of release of absorb-
able fatty acids. This can be translated into different
enzymatic dosage depending on the inherent-to-food
characteristics, so nutrition and dietary habits play a key
role in PERTeffectiveness.20 21
Moreover, the lack of appropriate tools and resources
for nutritional management can impair quality of life
and lead to a lack of treatment adherence. For instance,
if an incorrect nutritional behaviour or an inadequate
PERT dosage occurs, the most likely scenario is that it
will occur repeatedly and, in the majority of the cases, it
will not be detected and corrected until the next contact
at the CF unit. This could lead to long periods of omis-
sions and/or wrong decisions. Consequently, the small
daily actions related to nutrition that contribute to the
overall disease prognosis would not be optimally used to
improve the health status.
Hence, nutritional treatment in CF can be considered
as one of the ideal targets of mobile health (mHealth)
and patients’ self-management. In fact, CF is one of the
most representative examples in which patients’ moni-
toring and self-management can lead to a great improve-
ment in the evolution and prognosis of the disease.
Among other priorities in health, the current European
Union’s Research and Innovation Programme, Horizon
2020, strongly supports that current and future lines of
research and technological development should be
focused on this area (http://www.ec.europa.eu). In this
framework, the MyCyFAPP Project (http://www.
mycyfapp.eu) has been granted to develop an innovative
approach focused on paediatric children with CF, self-
management of nutrition and PERT by means of a
mobile application (APP) linked to a web-based profes-
sional management tool.
Figure 1 Overview of current
nutritional therapies in cystic
fibrosis and the tools needed for
successfully achieving a good
nutritional status, quality of life
and disease prognosis.
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The objective of the present work is to describe the
overall approach and study design of the MyCyFAPP
Project as an example of multidisciplinary research and
innovation project in mHealth.
METHODS
The consortium
The Consortium was established in 2015 with the sig-
nature of the grant agreement with the European
Commission. The multidisciplinary research team
comprises nutritionists–dieticians, paediatric gastroen-
terologists and pulmonologists, food engineers, IT
experts, game developers, software developers, psy-
chologists, sociologists, biologists and patients’ repre-
sentatives. We have brought together our expertise to
ensure the successful development of the project
through a holistic and integrative approach of the dif-
ferent and complementary areas of knowledge and
experts included.
There are 12 organisations involved: 6 clinical partners
linked to their corresponding research institutes or foun-
dations, 3 small–medium enterprises (SMEs) related
to mHealth, 1 Information and Communications
Technology (ICT) Research Institute, 1 Food Technology
Research Institute and the European Federation of
Patients with CF (table 1).
Funding
The MyCyFAPP Project is funded by the European
Union through the Horizon 2020 Research and
Innovation Programme (PHC-26-2014: self-management
of health and disease: citizen engagement and
mHealth) under grant agreement number 643806.
Study design
The 4-year long project (1 January 2015 to 31
December 2018) is constructed on nine inter-related
work packages (WP; ﬁgure 2). Four multidisciplinary
WP (1, 2, 3, 4) set the ground and generate the neces-
sary knowledge and resources to develop the APP. A
central technical WP (5) integrates the information in
the development of the different software tools. These
tools are thereafter tested for impact through a
European multicentre clinical trial (WP6) and once
the ICT tool is validated, another WP (8) takes care to
bring the tool to the market by following different busi-
ness models. Along the whole project, a speciﬁc WP (7)
ensures the dissemination of the project to the very
wide spectrum of audiences and another is devoted to
the coordination of the consortium and the manage-
ment of the implementation.
WP underpinning the project
European study on dietary habits in children with CF (WP1)
One of the ﬁrst actions of the project aims at obtaining
information related to nutritional habits and dietary
assessment of children with CF in the participating
countries. It is used to establish the current nutritional
habits of children with CF, PERT dosage, nutritional
status and dietary assessment as a ground setting. The
ﬁnal milestone is then the generation of educational
tools and resources for a customised nutritional self-
management of the disease and patients’ empowerment.
In vitro assessment of enzyme requirements for foods and
dishes (WP2)
In parallel to the development of the European survey,
we have set up a methodology to simulate in vitro diges-
tion of a wide range of foods and meals under standar-
dised CF gastrointestinal conditions. It allows for
characterising inherent-to-food factors (chemical com-
position, molecular structure of lipids, food matrix) and
gastrointestinal conditions (composition of digestive
ﬂuids and pH of the digestive environment), which
affect fatty acids release and enzyme activity. The ultim-
ate goal is to apply these results for determining the
optimal PERT doses for foods and meals. They conform
a key database supporting the mathematical algorithm.
Development of the PERT dose predictive model (WP3)
We conduct a pilot study with the enrolled children with
CF. They follow a ﬁxed menu consisting of a selection of
foods and ﬁxed enzyme doses according to the in vitro
studies (theoretical optimal dose, TOD). Analyses of fat
in stools reveal the degree of effectiveness of the pre-
dicted dose in each individual.
Biostatistical modelling of the results determines an
individual correction factor (ICF) calculation that will
be able to correct the in vitro dose, for any other meal
(even one not tested in the pilot study). Thus, from
WP2, the TOD estimates the requirements of PERT con-
sidering food characteristics. Then, from WP3, the ICF
will adjust the TOD according to patients’ individual
characteristics. These two key elements conform the pre-
dictive model, which calculates for each patient an indi-
vidual optimal dose.
User requirements specification for CF self-management
(WP4)
User requirements describe how software solutions work
in a certain context of use; how the end users will
beneﬁt from it; how the application is managed and
maintained; and how it is technically and organisation-
ally deployed. As already mentioned, MyCyFAPP is an
ecosystem of APPs, as well as a number of tools and com-
ponents devoted to support the execution of those
APPs.
It is critical to gather a multidisciplinary team (develo-
pers, clinical partners, psychologists, experts in user
experience and acceptance, paediatric and adult end
users and patients’ associations) to deﬁne in detail what
the mobile applications will do, and how the clinical pro-
cesses implemented through the web professional tool
will be perceived by the users, both children and care-
givers. MyCyFAPP has selected a methodology for the
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identiﬁcation of user requirements, called ‘co-creation’,
with the goal of maximising the opportunities for
further adoption.
A series of activities including interviews, focus groups
and hands-on workshops to establish the needs and pre-
ferences regarding the APP usage will be conducted. We
establish ﬁve focus groups (three patients and two
parents): patients aged >16 years, patients aged 12–16
years, patients <12 years, parents of patients aged 12–16
years and parents of patients younger than 12 years. The
APP will have different functions according to the
role and responsibility of the target group in the
self-management.
The results will be translated into tailored interfaces
and will be easily accessible and user-friendly for the dif-
ferent target populations.
Software development of APP and health professional
management tool (WP5)
The results from WP4 are translated into technical speci-
ﬁcations, and ﬁnally to software mobile and web applica-
tions. To this purpose, the system architecture, technical
speciﬁcations, integration plan and software testing strat-
egy are deﬁned. Finally, after software development for
full CF self-management, the implementation and inte-
gration of the algorithm developed in WP3 and the
Table 1 List of participating organisations in the MyCyFAPP Project
Country Organisation Type of activities
Spain Instituto de Investigación Sanitaria La Fe Non-profit organisation pursuing the fostering and
promotion of excellent research, scientific and technological
knowledge and the translation to the productive sector. It
manages research activities of Hospital La Fe, where the
regional CF unit is the reference.
Spain Soluciones TSB R&D and innovation SME focused on knowledge-intensive
solutions for healthcare and well-being.
Germany YOUSE GmbH Interdisciplinary SME working on increasing the usability
and user experience of products and services
Italy Imaginary SRL Experienced SME in creativity and innovation backed by
solid technical competence and an understanding of the
commercial potential of serious games and gamification
Norway STIFTELSEN SINTEF Research organisation with expertise within user-centred
design, software architecture, software development
methods, mobile and social computing and evaluation of
technology
Spain Universitat Politècnica de València—
Instituto de Ingeniería de Alimentos para el
Desarrollo
University Research Institute focused on food engineering.
It applies its strong experience in industrial food processing
to the area of the digestive food processing, involved in
numerous collaborative projects between the industry and
academia.
Belgium University of Leuven The CF reference centre is based at the University Hospital
of Leuven and has a strong research focus since many
years.
Portugal Associação Portuguesa para a Investigação
e Desenvolvimento da Faculdade de
Medicina
It is the funding body that supports medical research in the
Hospital de Santa Maria. The CF team conforms the
reference unit in the country.
Italy Università degli studi di Milano Research group linked to the Ospedale Maggiore Policlinico
with a wide experience in CF multicentre projects, which is
the largest CF reference unit in the region.
The Netherlands Erasmus Medical Center, Sophia Children’s
Hospital Rotterdam
The hospital embraces the reference CF unit for children in
the region. The medical team has a commitment to science
and research integrity and therefore is actively involved in
research projects.
Spain Servicio Madrileño de Salud. Hospital
Universitario Ramón y Cajal
The hospital is one of the reference CF units for children in
the region. The medical team has a broad experience in
clinical trials and research in the field of CF
Belgium Cystic Fibrosis Europe It is the representation of the Patients Organisations in
Europe, which is actively involved in dissemination of CF
activities and has been playing a key role in EU research
projects.
CF, cystic fibrosis; EU, European Union; R&D, research and development; SME, small–medium enterprise; TSB, Tecnológicas para la Salud
y el Bienestar.
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other resources developed in WP1 are conducted. At
that point, the overall system will be delivered for the
clinical trial in WP6.
Impact assessment through a European multicentre clinical
trial (WP6)
We will carry out a European multicentre clinical trial to
assess the impact derived from the usage of the APP on
children’s quality of life (especially related to nutrition
and gastrointestinal symptoms), nutritional status and
healthcare usage. A cohort of 200 patients will be
recruited. The sample size was estimated using Monte
Carlo simulations assuming normally distributed vari-
ables, and aiming for a precision of ±10% for each vari-
able. A validation step is crucial for implementing
MyCyFAPP in the usual clinical practice and transferring
the self-management utility to patients with CF.
Training and dissemination (WP7)
This WP embraces a double scope. Training activities are
aimed at achieving patient’s engagement in self-
management of their own disease so that speciﬁc work-
shops and webinars are scheduled prior to the start of
the clinical trial addressing both patients and health
professionals.
Dissemination pursues the project’s awareness,
through all media channels, among the key stake-
holders: patients and their families, patients’ associa-
tions, health authorities, professionals from the different
disciplines involved in the project, the industry and the
general public. Overall, it targets the successful imple-
mentation of MyCyFAPP.
Exploitation actions (WP8)
This WP takes care of the exploitation of the ﬁnal
product and the Intellectual Property Rights (IPR) pro-
tection plans envisaged in the project. Speciﬁc actions
include the identiﬁcation of business models for the
exploitation of the project’s outcomes, the deﬁnition
and execution of the strategy for exploitation and the
coordination of the exploitation activities with dissemi-
nations to maximise the impact and awareness of the
project.
Coordination and management (WP9)
It is aimed at orchestrating all the activities and partners
of the project towards the successful implementation of
the action and the reach of the goals and milestones.
EXPECTED RESULTS
The MyCyFAPP Project pursues a ﬁnal scenario where
children with CF and their families and the health pro-
fessionals can jointly and barriers-free manage the treat-
ment of the disease. On the one side, patients and
families count on the APP to self-manage nutrition and
PERT and, on the other, health professionals use the
professional tool to supervise and monitor patients’ pro-
gress, ensuring feedback between the two parts when
needed. This process is possible thanks to the speciﬁc-
ally developed procedures and tools (features) that are
Figure 2 General overview and inter-relation of WP. CF, cystic fibrosis; PERT, pancreatic enzyme replacement therapy; WP,
work packages.
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addressed in the framework of the project from a rigor-
ous scientiﬁc approach, responding to the current gaps
on the resources needed but not available for a success-
ful nutritional therapy (ﬁgure 3).
Tools and resources for MyCyFAPP
Throughout the ﬁrst WPs of the project, we conduct
research that results in the generation of the needed
tools and resources for the APP (ﬁgure 3A). The ‘math-
ematical predictive model’ of the optimal dose of
enzymes is the main feature, tackling the currently exist-
ing gap to successfully adjust PERT. It is fed by the ‘the-
oretical PERT doses database’ including the optimal
dose to digest a particular food or meal plus the ICF of
each patient. It becomes functional when the users indi-
cate the foods consumed and the amounts. A full and
‘interactive nutritional recommendations handbook’ is
also available in the APP supporting children’s dietary
habits towards avoiding and correcting nutritional imbal-
ances and reaching the recommendations. A ‘food and
symptoms record’ is automatically generated and stored
from the data introduced by the patients into the APP.
This feature works thanks to the calculation algorithms
and the ‘foods databases’, which include speciﬁc foods
and meals/recipes according to the survey on nutri-
tional habits and the complete nutritional proﬁle infor-
mation. The record allows for consulting at any time
patients’ progress in terms of nutritional composition of
their diets, their symptoms and the actions they have
performed in the system. ‘Educational games’ are devel-
oped in order to convey educational content of the
recommendations handbook to the youngest children
who cannot consult it. Games also have versions for
older patients, these being aimed at consolidating the
knowledge learnt by the other features. Finally, ‘alerts
and messages’ systems smooth the usability of the APP
between the two sides of MyCyFAPP—the patients and
the clinical teams—making the experience proﬁtable
and appealing.
Other speciﬁc features will be incorporated in the man-
agement system to enable health professionals to play
their role: the professional tool. This module contains
several features, such as a patients’ dashboard displaying
a summary of each patient—energy intake, percentage of
nutrients, symptoms, number of depositions, etc—from
where patients’ proﬁles (especially focused on nutrition)
can be accessed. Then ‘adjustment of parameters’ allows
for making a more focused follow-up and to set up goals,
and the ‘care plan management module’ is to deﬁne the
overall strategy for patient. Complementarily, an educa-
tion content management module and a report module
are in charge of creating a report to be sent to the
patients describing how they ﬁt to their personalised
plan. Through an iterative process with partners and ﬁnal
Figure 3 Summary of the project: generated tools (A), expected final scenario at the end of the project (B) and desired
outcomes (C). PERT, pancreatic enzyme replacement therapy.
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users, updates and corrections are periodically applied.
Thus, the ﬁnal set of features and tools will be decided
along the project.
The ultimate goal is to motivate the users to adhere to
the plan with positive messages when needed, and pro-
posing new challenges.
Final scenario
When the APP is ready to use (ﬁgure 3B), patients intro-
duce the food products or dishes and the APP indicates in
real time the optimal PERT dose for the particular meal
and considering the ICF of the patient. This, at the same
time, generates in real time a food record and its automatic
nutritional report. Complementary patients are already
taught and skilled to build up their menus according to
the dietary recommendations and, when needed, they are
offered to consult for suggestions or practical tips.
Some of the functions enabled by the interaction
between the patients and the clinical teams include the
periodic check of the daily results of the nutritional
proﬁle of the diet. The software is programmed to alert
patients and medical teams in case of a deviation from
general or personalised recommendations (eg, percent-
age of lipids does not reach the threshold this week). If
a deviation is identiﬁed as relevant—according to the
deﬁnition of a risk and the plan for the patient—the
health professionals can be notiﬁed, through the profes-
sional web tool, and are then responsible to decide
which correction procedure has to apply (eg, consult
educational resource number 1.3). For some situations,
however, the software is programmed to automatically
pop up reaction messages. Thus, the overall aim is to
provide feedback and assistance to the patients outside
the scheduled face-to-face visits.
Of note, the aforedescribed situation is thoroughly
assessed through a multicentre clinical trial that will
allow for the identiﬁcation of errors and the features
and procedures showing room for improvement.
Therefore, updates and modiﬁcations can be applied
before upgrading the system to the ﬁnal and fully func-
tional version. If success in the clinical validation occurs,
MyCyFAPP can be able to reach the market by following
the deﬁned exploitation plan.
Desired outcomes
Overall, we expect that the mHealth solution contributes
to reach the project’s goals: an evidence-based method
for PERT adjustment, reaching nutritional goals and
close nutritional follow-up. The desired outcomes
derived from its long-term usage are a triple improve-
ment: quality of life speciﬁcally related to gastrointestinal
symptoms, nutritional status and disease prognosis
(ﬁgure 3C).
CONCLUSION
Through MyCyFAPP, we have brought together highly
experienced professionals from various European
countries with different areas of knowledge to jointly
address the challenges faced by adequate nutrition and
PERT in the management of CF. We mainly tackle two
gaps within the project: ﬁrst, we develop from scratch
the required tools for effective PERT and nutritional
therapy; second, we make the tools available to patients,
enabling effective adherence to the disease treatment
through self-management but still, when needed, main-
taining a close and dynamic interaction with the medical
teams throughout the mHealth tool.
The beneﬁciaries of the projects’ results comprise
patients, caregivers, families and healthcare profes-
sionals. MyCyFAPP is designed in a tailored way and
clinically tested for CF self-management and monitor-
ing. Additionally, MyCyFAPP has a pivotal role as a deci-
sion support system and provides a solution to the
current gaps in the treatment. The participating SMEs
and business models will ensure the commercial ex-
ploitation of the results, the market uptake and the
MyCyFAPP distribution for the beneﬁt of the patients.
We envisage a prominent impact on nutritional status,
quality of life and overall disease prognosis in the near
future.
When people ask me to provide an example of how patients,
caregivers, researchers, a Foundation, NIH and industry can
all work together to ﬁnd cures, I point to cystic ﬁbrosis. It’s
the very best example. Francis S Collins, MD, PhD, Director
of the National Institutes of Health and a member of the
international team that discovered the CF gene
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